Ironwood Pharmaceuticals Inc.

Last updated September 27, 2026

Organization details

Legal name
Ironwood Pharmaceuticals Inc.
Ownership
Public
Status
Active
Sector (GICS)
Health Care
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
Boston
Headquarters state / province
Massachusetts
Headquarters country
United States
Fiscal year end
December
Ticker symbol
IRWD
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001446847
EIN
04-3404176
Wikidata ID
Q16997309

Board of directors

Chief executives

Thomas A. Mccourt · Chief Executive Officer
Dates unknown

Director election results

Annual meeting of June 16, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

5 of this board's directors also sit on 5 other boards. 5 are in the same sector.

Network of Ironwood Pharmaceuticals Inc.'s board connections Alto Neuroscience Inc. Alto Neuroscience Inc. Inovio Pharmaceuticals Inc. Inovio Pharmaceuticals... Lantheus Holdings Inc. Lantheus Holdings Inc. MoonLake Immunotherapeutics MoonLake Immunotherape... Pliant Therapeutics Inc. Pliant Therapeutics In... Andrew Dreyfus Andrew Dreyfus Catherine Moukheibir Catherine Moukheibir Jay Shepard Jay Shepard Julie McHugh Julie McHugh Thomas A. Mccourt Thomas A. Mccourt Ironwood Pharmaceuticals I...
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$22,621,971
18 sales by 8 insiders
Date Insider Transaction Shares Price Value
Sep 15, 2026 Alexander J. Denner Director Grant or award +3,694 — —
Jul 20, 2026 Silber Jeffrey Officer (SVP, CMO, Head-Res&Drug) Grant or award +137,036 — —
Jul 7, 2026 Silver Ronald Officer (PFO & PAO) Open-market sale −127,890 $4.52 $578,063
Jun 16, 2026 Jay Shepard Director Grant or award +63,481 — —
Jun 16, 2026 Marla L. Kessler Director Grant or award +63,481 — —
Jun 16, 2026 Mark G. Currie Director Grant or award +63,481 — —
Jun 16, 2026 Jon R. Duane Director Grant or award +63,481 — —
Jun 16, 2026 Julie McHugh Director Grant or award +63,481 — —
Jun 16, 2026 Catherine Moukheibir Director Grant or award +63,481 — —
Jun 16, 2026 Alexander J. Denner Director Grant or award +63,481 — —
Jun 16, 2026 Julie McHugh Director Open-market sale −21,571 $3.73 $80,460
Jun 15, 2026 Alexander J. Denner Director Grant or award +4,065 — —
May 19, 2026 Silver Ronald Officer (PFO & PAO) Grant or award +25,000 — —
Mar 17, 2026 Alexander J. Denner Director Open-market sale −6,725,000 $3.05 $20,511,250
Mar 17, 2026 Alexander J. Denner Director Open-market sale −5,800 $3.31 $19,198

Organizations in the same sector, closest in location and size first.

Questions about Ironwood Pharmaceuticals Inc.

Who is the CEO of Ironwood Pharmaceuticals Inc.?

Thomas A. Mccourt is Ironwood Pharmaceuticals Inc.'s Chief Executive Officer.

How many directors are on Ironwood Pharmaceuticals Inc.'s board?

Ironwood Pharmaceuticals Inc.'s board has 9 directors: Alexander J. Denner, Andrew Dreyfus, Catherine Moukheibir, Jay Shepard, Jon R. Duane, Julie McHugh, Mark G. Currie, Marla L. Kessler and Thomas A. Mccourt.

Are Ironwood Pharmaceuticals Inc. insiders buying or selling shares?

Over the last 12 months, Ironwood Pharmaceuticals Inc. insiders made no open-market purchases and sold $22.6 million of shares in 18 sales on the open market, as reported to the SEC on Forms 4 and 5.

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="ironwood-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.